LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$18.54 USD
-0.09 (-0.48%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $18.56 +0.02 (0.11%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
Cash flow Statements
Fiscal Year End for LENZ Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -124.65 | -101.05 | -70.76 | -68.37 | -0.11 |
Depreciation/Amortization & Depletion | 3.95 | 0.75 | 0.73 | 0.12 | 0.00 |
Net Change from Assets/Liabilities | -39.22 | -7.21 | -2.50 | 1.71 | 0.01 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 69.92 | 19.53 | 19.67 | 57.82 | 0.08 |
Net Cash From Operating Activities | -90.01 | -87.98 | -52.85 | -8.72 | -0.02 |
Property & Equipment | -8.95 | -6.59 | -5.74 | -1.55 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 235.30 | -235.27 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 226.35 | -241.86 | -5.74 | -1.55 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.19 | 0.60 | 166.14 | 25.08 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 5.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 251.32 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.19 | 0.60 | 417.47 | 30.08 | 0.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 136.53 | -329.25 | 358.88 | 19.81 | -0.02 |
Cash at Beginning of Period | 49.45 | 378.69 | 19.82 | 0.01 | 0.03 |
Cash at End of Period | 185.98 | 49.45 | 378.69 | 19.82 | 0.01 |
Diluted Net EPS | -15.33 | -12.88 | -17.14 | -209.45 | NA |
Fiscal Year End for LENZ Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -16.65 | -124.65 | -101.73 | -79.25 | -23.93 |
Depreciation/Amortization & Depletion | -0.27 | 3.95 | -1.16 | -0.96 | -0.91 |
Net Change from Assets/Liabilities | -9.01 | -39.22 | 3.30 | 2.06 | -1.06 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.99 | 69.92 | 55.46 | 43.43 | 4.83 |
Net Cash From Operating Activities | -23.94 | -90.01 | -44.13 | -34.73 | -21.07 |
Property & Equipment | 0.00 | -8.95 | -9.58 | -5.66 | -0.38 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 18.00 | 235.30 | 188.85 | 121.05 | 43.55 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 18.00 | 226.35 | 179.26 | 115.39 | 43.16 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 53.82 | 0.19 | 0.12 | 0.12 | -0.01 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 117.45 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 171.27 | 0.19 | 0.12 | 0.12 | -0.01 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 165.33 | 136.53 | 135.26 | 80.78 | 22.08 |
Cash at Beginning of Period | 35.14 | 49.45 | 49.45 | 49.45 | 49.45 |
Cash at End of Period | 200.47 | 185.98 | 184.70 | 130.22 | 71.53 |
Diluted Net EPS | -3.53 | -2.80 | -2.73 | -6.79 | -3.01 |